Fig. 3

The top clinically relevant S-phase lncRNAs regulate crucial cancer cell hallmarks. a Kaplan–Meier plots of SCAT1 ̶SCAT8 indicating overall survival of patients in KIRC. The higher expression of all SCATs is correlated with poor overall survival. The expression cut-off and the significance value for each SCAT are indicated in the plots. UQ represents upper quartile of the patients’ expression levels. The Forest plots represent the multivariate models derived for each SCAT in combination with the significant clinical parameters. The hazard ratio (HR) using Cox proportional hazard analysis and the associated p-values were calculated using Wald statistics. b Proliferation capacity of HeLa cells as measured by MTT colorimetric assay 48 h post-silencing of SCATs using two different LNAs (SCAT1, SCAT2, SCAT4, SCAT5, and SCAT6) or siRNAs (SCAT3 and SCAT7). Data are represented as percentage compared to cells transfected with respect to the negative control. No significant difference was observed between LNA-negative control and siRNA-negative control. c Cell cycle profiles of HeLa cells depleted with two different LNAs or siRNAs targeting the seven SCATs. d Estimation of the caspase 3/7 activities 48 h post-silencing of SCATs in HeLa cells. Data are expressed as fold change with respect to the corresponding negative controls. e MTT proliferation assay of Caki-2 (KIRC) cell line depleted with two independent LNAs (SCAT4, SCAT8) or siRNAs (SCAT7). f Cell cycle profiles of Caki-2 cells depleted with two different LNAs or siRNAs. g Estimation of the caspase 3/7 activities 48 h post-silencing of the corresponding SCAT in Caki-2 cells. Data in b–g are shown as mean ± SEM of three independent experiments. Significance levels were derived using unpaired two-tailed Students’ t-test. (*p ≤ 0.05; **p = 0.01 ̶ 0.001; ***p < 0.001)